Table 2 Basic Demographics

n

984

954

30

 Age, mean (SD)

63.1 (7.2)

62.9 (7.2)

68.2 (6.3)

< 0.0001 ¥

 Female gender, n (%)

357 (36%)

346 (36%)

11 (37%)

0.964 £

 BMI, mean (SD)

26.8 (5.9)

26.8 (5.8)

27.3 (7.8)

0.777 ¥

 Pack-years, mean (SD)

47.4 (26.0)

47.1 (25.3)

55.9 (42.5)

0.934 ¥

 Current smokers, n (%)

363 (37%)

360 (38%)

3 (10%)

0.002 £

 Cardiovascular history, n (%)

310 (32%)

298 (31%)

12 (40%)

0.309 £

 Post bronchodilator FEV₁ (% predicted), mean (SD)

50.6 (15.2)

50.6 (15.3)

48.5 (13.0)

0.384 ¥

GOLD stage, n (%)

0.695 £

 2

487 (49%)

473 (50%)

14 (47%)

 3

397 (40%)

383 (40%)

14 (47%)

 4

100 (10%)

98 (10%)

2 (7%)

GOLD stage, n (%)

0.231 £

 A

250 (25%)

244 (26%)

6 (20%)

 B

128 (13%)

121 (13%)

7 (23%)

 C

226 (23%)

222 (23%)

4 (13%)

 D

339 (34%)

329 (34%)

10 (33%)

 mMRC score, median (IQR)

1 (1–2)

1 (1–2)

2 (1–3)

0.022 ¥

 SGRQ-C total score, median (IQR)

47.2 (33.2–60.6)

47.2 (33.2–60.2)

53.3 (33.0–66.0)

0.294 ¥

 6MWD (meters), mean (SD)

385.4 (119.0)

387.0 (119.1)

335.3 (105.0)

0.013 ¥

 FV950 baseline, mean (SD)

16.3 (11.3)

16.2 (11.3)

17.4 (10.5)

0.425 ¥

 Emphysema (%LAA ≥ 10%), n (%)

558 (57%)

538 (56%)

20 (67%)

0.264 £

 Number of hospitalized exacerbations in year prior to study, mean (SD)

0.16 (0.53)

0.16 (0.52)

0.37 (0.85)

0.036 ¥

 BODE index, median (IQR)

3.0 (1.0–4.0)

3.0 (1.0–4.0)

3.5 (2–5)

0.065 ¥

 Dead by end of study, n (%)

30 (3%)

0 (0%)

30 (100%)

< 0.0001 £

 Survival time (days), mean (SD)

1056 (28)

1060 (0)

922 (84)

< 0.0001 ¥

 C4Ma3 (ng/mL), median (IQR)

3.28 (2.55–4.33)

3.25 (2.54–4.30)

4.02 (3.16–6.05)

0.0008 ¥

 TUM (ng/mL), median (IQR)

0.71 (0.69–0.74)

0.71 (0.69–0.73)

0.79 (0.71–1.17)

0.0467 ¥

 Fibrinogen (mg/dL), median (IQR)

378.4 (334.4–434.1)

377. 6 (333.5–432.0)

445.4 (359.4–527.0)

0.0006 ¥